Completed Clinical Trials

An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE)

ClinicalTrials.gov ID NCT06179875
Sponsor Viridian Therapeutics, Inc.

This study provides VRDN-001 (experimental antibody that blocks a protein called IGF-1R) to participants from two previous studies (THRIVE and THRIVE-2) who did not show sufficient improvement with their original treatment, allowing researchers to evaluate whether additional or different VRDN-001 treatment can help these participants.

https://clinicaltrials.gov/study/NCT06179875

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) (TED)

ClinicalTrials.gov ID NCT05683496
Sponsor ACELYRIN Inc.

This early-stage study (phase ½) tests different doses of lonigutamab, an experimental treatment, in people with thyroid eye disease to determine how safe and effective it is.

https://clinicaltrials.gov/study/NCT05683496

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

ClinicalTrials.gov ID NCT06226545
Sponsor Lassen Therapeutics Inc.

LASN01 is an experimental antibody treatment for thyroid eye disease given through IV infusion. This Phase 2 study evaluates the safety and effectiveness of LASN01 in four treatment groups: three groups for patients who haven’t received previous anti-IGF-1R treatments, and one group for patients who previously received teprotumumab treatment.

https://www.clinicaltrials.gov/study/NCT06226545

A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) (THRIVE)

ClinicalTrials.gov ID NCT05176639
Sponsor Viridian Therapeutics, Inc.

This study tests the safety, tolerability, and effectiveness of veligrotug at a 10 mg/kg dose in people with active thyroid eye disease, while also measuring how the body processes and responds to the medication. Veligrotug (VRDN-001) is an experimental antibody that blocks the protein IGF-1R which may help reduce eye inflammation and swelling in thyroid eye disease.

https://www.clinicaltrials.gov/study/NCT05176639